Clinical Trials Disclosure Code From International Group Covers All Studies Of Life-Threatening Conditions
This article was originally published in The Pink Sheet Daily
Executive Summary
IFPMA says policy covers early stage safety trials -- a subset not mentioned in PhRMA's Clinical Trial Code.
You may also be interested in...
Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space
Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space
PhRMA Clinical Trial Code: Disclosure Edition
PhRMA is using broad disclosure as a defense against questions of clinical trial bias. Disclosure used to be a penalty forced on firms in consent decrees and lawsuits; now it appears as a pillar to building trust for corporate-sponsored trials.